vialaudit
MOTS-C·US LEGAL STATUS·LAST CHECKED 1 NOV 2026

Is MOTS-c legal?

Not as a drug. MOTS-c has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. Under an interim HHS policy of 28 October 2026, a licensed pharmacy may compound it against a prescription, by set routes and under strict conditions, without federal enforcement. That policy does not cover research-use-only vials sold online.

RESEARCH-LABELLED SALE
Unapproved drug
PHARMACY COMPOUNDING
Under conditions · HHS policy Oct 2026
PRESCRIPTION
No approved product
WADA 2026
Prohibited (S4.4.1)

DESCRIBES THE LAW · NOT LEGAL ADVICE · NO DOSING INFORMATION

Federal, compounding and sport status

CHECKED 1 NOV 2026

Federal status

FDA approval
investigational
DEA scheduling
not scheduled
503A compounding
FDA interim category: Nominated but withdrawn (off Category 2, not eligible)
503A Bulks List: pcac recommended
HHS interim policy (Oct 28, 2026): no enforcement against licensed 503A compounding with a prescription · routes: subcutaneous or intramuscular (acetate) · FEDERAL REGISTER ↗
Still not on the 503A Bulks List and not an approved drug. Removed from Category 2 on 15 Apr 2026. In July 2026 the PCAC recommended it for the Bulks List (obesity, osteoporosis). On 28 Oct 2026 HHS issued an interim 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances' (Federal Register 30 Oct 2026, 91 FR 68526). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, Federal facility or licensed physician compounding MOTS-c against a patient-specific prescription, limited to subcutaneous or intramuscular, as a single ingredient, from API made by an FDA-registered facility with a full certificate of analysis. The Federal Register notice calls the policy a draft that is not binding; comments close 13 Nov 2026 (docket HHS-OASH-2026-0496). It does not cover 503B outsourcing facilities or research-use-only vials sold online.
PCAC review history
  • Jul 23, 2026 · recommended · 7 yes, 5 no, 2 abstentions (law-firm reports) · SOURCE ↗
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: Same posture as other unapproved peptides — RUO label is not a safe harbor.
Personal possession: Not federally scheduled; possession is not a federal crime.

Sport-body status

WADA 2026
prohibited · class S4.4.1 · in and out of competition
Named under S4.4.1 as an AMPK activator (mitochondrial open reading frame of the 12S rRNA-c). Prohibited at all times.
USADA
NCAA
unknown

What we couldn’t verify

MOTS-c US legal status, checked 12 Oct 2026: research sale Unapproved drug, compounding Not yet · PCAC recommended Jul 2026, prescription No approved product, WADA 2026 Prohibited (S4.4.1), 0 FDA warning letters
MOTS-c federal, compounding and sport status, checked 12 Oct 2026. Describes the law, not legal advice.

State rules

1 STATE
compounding restriction · Indiana

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound MOTS-c: in Indiana the ingredient could not be research grade.

MOTS-c in Indiana

In the other states we found nothing that names MOTS-c; federal law applies.

What changed at the last check

7 CHANGES
DateFieldWasNowWhy
1 Nov 2026503A compounding (HHS policy)not compoundable; reported HHS stopgap not issuedHHS enforcement discretion under conditions (interim, not on Bulks List)HHS filed its peptide enforcement discretion policy on 28 Oct 2026 (FR doc 2026-22192, published 30 Oct). MOTS-c is one of six peptides in Appendix A. HHS says it will not act against licensed 503A compounding with a prescription, routes limited to subcutaneous or intramuscular. Comments close 13 Nov 2026. source ↗
12 Oct 2026503A Bulks List statusunder pcac reviewpcac recommendedNot eligible as of 12 Oct 2026. Removed from Category 2 on 15 Apr 2026; the PCAC recommended it (obesity, osteoporosis) in July 2026. source ↗
12 Oct 2026FDA Category 2 (safety risk)under pcac reviewnot on listFDA's Category 2 page lists it under 'nominated but withdrawn', not in Category 2. source ↗
12 Oct 2026WADA 2026prohibited (S2)prohibited (S4.4.1)Named under S4.4.1 as an AMPK activator (mitochondrial open reading frame of the 12S rRNA-c). Prohibited at all times. source ↗
12 Oct 2026OH state noteOhio BOP Feb 2026 peptide compounding guidance directs cessation of Category 2 style peptide preparation including MOTS removedRemoved. The entry described a OH action that does not name MOTS-c; it applied federal-level or class-wide facts by analogy. source ↗
12 Oct 2026IN state notenoneaddedSince 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound MOTS-c: in Indiana the ingredient could not be research grade. source ↗
12 Oct 2026PCAC reviewpending (vote scheduled)voted yesPCAC vote on 2026-07-23: 7 yes, 5 no, 2 abstentions (law-firm reports). source ↗

Questions

3 ANSWERS
Is MOTS-c legal in the US?

Not as a drug. MOTS-c has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. Under an interim HHS policy of 28 October 2026, a licensed pharmacy may compound it against a prescription, by set routes and under strict conditions, without federal enforcement. That policy does not cover research-use-only vials sold online.

Can a pharmacy compound MOTS-c?

Still not on the 503A Bulks List and not an approved drug. Removed from Category 2 on 15 Apr 2026. In July 2026 the PCAC recommended it for the Bulks List (obesity, osteoporosis). On 28 Oct 2026 HHS issued an interim 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances' (Federal Register 30 Oct 2026, 91 FR 68526). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, Federal facility or licensed physician compounding MOTS-c against a patient-specific prescription, limited to subcutaneous or intramuscular, as a single ingredient, from API made by an FDA-registered facility with a full certificate of analysis. The Federal Register notice calls the policy a draft that is not binding; comments close 13 Nov 2026 (docket HHS-OASH-2026-0496). It does not cover 503B outsourcing facilities or research-use-only vials sold online.

Is MOTS-c banned in sport?

Yes. It is prohibited at all times under WADA 2026 class S4.4.1. Named under S4.4.1 as an AMPK activator (mitochondrial open reading frame of the 12S rRNA-c). Prohibited at all times.

Sources

10 DOCUMENTS
  1. FDA approval record
  2. DEA controlled-substance schedules
  3. FDA 503A compounding position
  4. HHS peptide enforcement discretion policy, Federal Register
  5. PCAC review, 23 Jul 2026
  6. WADA 2026 Prohibited List
  7. Indiana Senate Enrolled Act 282 (Public Law 136-2026), signed 5 Mar 2026
  8. SEA 282 enrolled text
  9. Source for: FDA Category 2 (safety risk)
  10. Source for: OH state note
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH